Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males

Next Previous
Search
Trial Profile

Pharmacokinetics of Levodopa, Carbidopa, 3-OMD and ODM-104 After Repeated Doses of Different Formulations: an Open, Randomised, Multicentre Study With Crossover Design in Healthy Males

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ODM 104 (Primary) ; Carbidopa; Levodopa; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Acronyms NOCOF
  • Sponsors Orion

Most Recent Events

  • 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
  • 17 Feb 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 12 Dec 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top